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Abstract
Mutations in the gene-encoding cystic fibrosis transmembrane conductance regulator (CFTR) cause defective transepithelial
transport of chloride (Cl
2) ions and fluid, thereby becoming responsible for the onset of cystic fibrosis (CF). One strategy to
reduce the pathophysiology associated with CF is to increase Cl
2 transport through alternative pathways. In this paper, we
demonstrate that a small synthetic molecule which forms Cl
2 channels to mediate Cl
2 transport across lipid bilayer
membranes is capable of restoring Cl
2 permeability in human CF epithelial cells; as a result, it has the potential to become a
lead compound for the treatment of human diseases associated with Cl
2 channel dysfunction.
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Introduction
Chloride (Cl
2) ion channels that mediate the flow of Cl
2 ions
through cell membranes play crucial roles in regulating a broad
range of biological processes, including ion homeostasis, cell
volume regulation, transepithelial transport and the regulation of
electrical excitability [1]. The malfunctioning of Cl
2 channels is
implicated in many severe human diseases, most notably cystic
fibrosis (CF) [2,3]. In CF, mutations in the gene-encoding cystic
fibrosis transmembrane conductance regulator (CFTR), a Cl
2
channel located at the apical membranes of epithelial cells, causes
defective transepithelial transport of Cl
2 and fluid [4–7]. A
general strategy for reducing the pathophysiology associated with
CF mutations is to increase the Cl
2 permeability of epithelial cells
either through CFTR correctors or potentiators or via alternative
pathways to compensate for the CFTR Cl
2 channel defect. Great
efforts have been made to develop gene transfer of the CFTR to
epithelia [8–11] and therapeutic agents that can activate mutant
CFTR genes [12], rescue mutant CFTR trafficking to the apical
surface of epithelial cells [13,14], suppress premature stop
mutations located in the CFTR gene [15–17] or activate
alternative natural Cl
2 channels [7,17–20]. Denufosol acting on
the P2Y2 receptor opens up an alternative chloride channel
resulting in Cl
2 ion and liquid secretion, and partly compensates
for effects caused by the mutant CFTR [19]. However, denufosol
has recently failed phase III clinical trials. Therefore, the
development of synthetic Cl
2 channels [21–32] provides a brand
new opportunity to enhance transepithelial Cl
2 secretion for the
treatment of CF.
To date, however, most reported synthetic ion channels have
been characterized in artificial lipid bilayers, and biological
applications of these synthetic Cl
2 channels to increase the Cl
2
permeability of living cells remain poorly explored [33]. Moreover,
because most of these synthetic Cl
2 channel-forming compounds
have relatively complicated structures and high molecular weights
[22–33], their application to drug discovery is restricted. In this
study, we report on a small molecule that can form Cl
2 channels
in plasma membranes of living cells. This synthetic Cl
2 channel is
capable of increasing Cl
2 conductance in human CF epithelial
cells.
We recently reported that the small molecule 1 (Figure 1, panel
a) mediates Cl
2 transport across lipid membranes [34]. The
typical single-channel currents we observed for this molecule in
giant liposomes confirmed the formation of ion channels [34].
Here, we address the electrophysiological properties and potential
functions of this synthetic Cl
2 channel in living cells.
Results and Discussion
We first performed inside-out single channel recording, a patch
clamp technique [35], to identify the formation of ion channels by
compound 1 in HEK 293 cells, a widely used cell line in ion
channel research. In the presence of 1 mM of compound 1, the
typical single-channel currents were indeed recorded in symmetric
N-methylglucamine hydrochloride (NMDG-Cl) solutions (Figure 1,
Panel b), indicating that the small molecule can self-assemble into
functional ion channels in the cell membranes. Similar to single-
channel recording with compound 1 in liposomes, various
conductances were observed in the same or different patches,
which was anticipated for molecules that self-assemble into ion
channels of various sizes [22–33].
We then used the whole-cell configuration of patch clamp
technique to examine the electrophysiological properties of the
ionic currents induced by compound 1 in HEK 293 cells. Whole-
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intracellular and extracellular solutions (see Methods). While the
vehicle (0.1% DMSO) had no effect on the whole-cell currents
(Figure S1), compound 1, even at a low concentration of 1 mM,
induced a large current increase relative to that of the control
(Figure 2, Panels a and b). To confirm that the increase in whole-
cell currents was caused by the formation of synthetic Cl
2
channels, we next recorded the whole-cell currents in symmetric
bath and pipette solutions of NMDG-Cl. As expected, there was
no obvious difference in the whole-cell currents elicited by
compound 1 when the cations (Na
+,C s
+ and Mg
2+) used in the
standard bath and pipette solutions were replaced by the larger
NMDG cation (Figure 2, Panels b and c), which is known to be
impermeable through most natural cation channels. However,
when the NMDG-Cl bath solution was changed from symmetric
150 mM to asymmetric 50 mM, the outward current decreased to
a remarkable extent and the cell reverse potential (Erev) shifted
from 0 to 26.9961.38 (n=5) mV, which is quite close to the value
of the Cl
2 reverse potential (ECl) (27.76 mV) calculated from the
Nernst equation. Taken together, these results indicate that the ion
channels formed by compound 1 are permeable to Cl
2 ions only,
and not to NMDG ions, and the increased whole-cell currents
observed in previous experiments can therefore be attributed to
the Cl
2 currents induced by synthetic Cl
2 channels rather than to
a non-specific membrane leak.
We next investigated the anion selectivity of this synthetic Cl
2
channel by comparing cell reverse potentials when replacing the
extracellular Cl
2 ions with equimolar F
2,B r
2,I
2, and NO3
2
ions. The relative permeability ratios against Cl
2 (F
2 :C l
2 :B r
2 :
I
2 :N O 3
2) were determined to be 0.673 : 1 : 1.121 : 1.251 : 1.358
(Figure 3), i.e., the anion transport activity of the synthetic Cl
2
channel follows the sequence F
2,Cl
2,Br
2,I
2,NO3
2. Mean-
while, the same anion over cation selectivity and relative transport
activity toward various anions in patch-clamp studies have also
been observed in fluorescence assays performed in liposomes
(Figure S2, Panels a and b). Moreover, in our effort to search for
potential inhibitors of this synthetic Cl
2 channel, we examined the
effects of a variety of commonly used blockers of natural Cl
2
channels. Unfortunately, all the inhibitors tested (DIDS, DPC,
NFA, SITS and NPPB) failed to block the whole-cell currents
induced by compound 1 (Figure S3). This result was not
unexpected given that the synthetic Cl
2 channel may have very
different structural features from those of natural ones.
To determine the potential of using compound 1 in the
treatment of CF, the final step of our analysis involved
investigating whether compound 1 could be incorporated into
the plasma membranes of CF cells and, thereby, function as a Cl
2
channel to increase the Cl
2 permeability of these cells. We
recorded the whole-cell currents induced by compound 1 in CuFi-
8 and NuLi-1 cells, [34] which were derived from the human
bronchial epithelia of a patient with CF (CuFi-8, homozygous
CFTR DF508 mutant) and a subject without CF (NuLi-1, wild
type CFTR), respectively. The application of compound 1 induced
a gradual increase in the whole-cell currents in the first few
minutes, after which the currents became stable for 15 minutes.
The currents were persistent even after washing out the cells with
control buffer for 30 minutes (Figure 4, Panel b). Interestingly,
even at a low concentration of 1 mM, compound 1 induced very
large whole-cell currents relative to the basal currents (Figure 4,
Panels a and b). The whole-cell currents of the CF cells treated
with compound 1 displayed a slightly voltage-dependent current-
voltage relationship similar to that seen in HEK 293 cells.
Furthermore, panel c of Figure 4 reveals that the addition of
forskolin (2 mM), an agonist of cAMP, led to a large increase in the
Cl
2 currents of the normal human airway epithelial cells (NuLi-1),
whereas the CF cells (CuFi-8) exhibited little response to forskolin.
In contrast, the addition of 1 mM compound 1 resulted in an even
larger increase in the whole-cell currents of the CuFi-8 cells than
that recorded in those of the NuLi-1 cells treated with 2 mM
forskolin, indicating that compound 1 is capable of increasing Cl
2
conductance in these CF cells via a novel pathway. Similarly,
compound 1 also increased Cl
2 conductance in NuLi-1 cells. The
compound 1-induced Cl
2 current was a little smaller than that
recorded in CuFi-8 cells. Because compound 1 is generated from
an a-aminoxy acid unit, in considering the possibility of applying
compound 1 in future, we also examined its toxicity in, for
example, immune response in animals. The data showed that
compound 1 did not induce mouse immune response, especially in
lung tissue (Figures S4 and S5, Methods S1). However, even
though compound 1 exhibited a very good ability to restore the
Cl
2 permeability of CF airway epithelial cells and had low toxicity
in animals, we still cannot conclude that it can be used to treat CF
in practice. Further experiments based on a CF animal model
should provide better evidence confirming the therapeutic
potential of compound 1. At this stage, we provide a preliminary
report of our findings.
In conclusion, we have demonstrated that compound 1 forms
functional Cl
2 channels not only in lipid bilayer membranes
of liposomes, but also in those of live cells, as revealed by both
single-channel and whole-cell patch clamp experiments. More
Figure 1. Chemical structure and single channel currents of compound 1 in HEK 293 cells. (a) Chemical structure of compound 1.( b)
Representative traces showing single channel currents with DMSO control (top trace) and the application of 1 mM compound 1 (lower four traces) at
260 mV in HEK 293 cells. ‘‘C’’ represents the base line in which the channel is in the close state.
doi:10.1371/journal.pone.0034694.g001
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2
permeability of CF airway epithelial cells with defects in their
native CFTR Cl
2 channels. In light of these observations, this
compound may have therapeutic potential for the treatment of CF
lung disease or for treating other diseases that might benefit from
increased Cl
2 transport.
Methods
Cell culture
The HEK 293 cell line obtained from the American Type
Culture Collection was cultured in DMEM supplemented with
10% FBS, 100 IU/ml penicillin G and 0.1 mg/ml streptomycin.
NuLi-1 and CuFi-8 cells, a generous gift from Prof. Joseph Zabner
(University of Iowa, Iowa City, IA), were derived from the human
bronchial epithelia of a patient without CF (NuLi-1, WT CFTR)
and a subject with CF (CuFi-8, homozygous CFTR DF508
mutant), respectively. These cell lines were grown on human
placental collagen type VI (Sigma)–coated flasks in BEGM
(Cambrex Bio Science, Walkersville, MD) medium, which includes
BEGM basal medium and eight SingleQuots of supplements. Cells
were grown at 37uC in a 5% CO2 humidified incubator.
Electrophysiology
The single channel current was recorded using an EPC 9 patch
clamp amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany)
in voltage-clamp mode, controlled by Pulse/PulseFit 8.7 software
(HEKA) with inside-out patch configuration. Patch pipettes
(resistance, 10–20 MV) were filled with internal pipette solution
containing 150 mM NMDG-Cl and 10 mM HEPES (pH 7.2).
The bath was composed of symmetric 150 mM NMDG-Cl and
10 mM HEPES (pH 7.2) with 200 mM diphenylamine-2-carbox-
ylic acid that blocks native Cl
2 channels. After the inside-out
recording was achieved without any channel opening, 1 mM
compound 1 was perfused into the bath. The single channel
current was recorded continuously and sampled at 4 kHz, and was
typically low-pass filtered at 0.4 kHz with an 8-pole Bessel filter.
In the whole-cell current recording of the HEK 293, NuLi-1
and CuFi-8 cells in the standard bath (NaCl 140, CsCl 5, CaCl2 1,
MgCl2 1 and HEPES 10 in mM, pH 7.4 with CsOH) and pipette
(CsCl 140, MgCl2 1, HEPES 10, EGTA 5 and Na2ATP 5 in mM,
pH 7.2 with CsOH) solutions, the cells were held at 0 mV and
voltage steps ranging from 2100 to +100 mV were applied for
800 ms in 20-mV step increments. In these experiments, the
native K
+ currents were eliminated by using K
+-free intra- and
Figure 2. Electrophysiological properties of the ion channels formed by compound 1 in HEK 293 cells. (a) Representative traces
showing whole-cell currents in HEK 293 cells. The upper panel shows the stimulation protocol for whole-cell recording, and the lower left panel
shows DMSO control currents. The right panel shows whole-cell currents after the application of 1 mM compound 1.( b) Current–voltage relationships
obtained in the absence (#) and presence (N)o f1mM compound 1 and after washout (m) with the control bath solution for 30 min in HEK 293 cells.
(c) Representative traces showing the whole-cell ramp currents recorded in symmetric 150 mM NMDG-Cl (black trace) and asymmetric NMDG-Cl with
150 mM in internal and 50 mM in external solutions (red trace). All data are means 6 s.e. n=5–6.
doi:10.1371/journal.pone.0034694.g002
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native Ca
2+ or Na
+ channels were inactivated by using a holding
potential of 0 mV. Internal free Ca
2+ was chelated by EGTA in
pipette solution to prevent Ca
2+-dependent channels from being
activated. Changes in the whole-cell currents were detected from
the same cells before and after exposure to the bath solution
containing compound 1 (1 mM, 1 mM stock in DMSO) or
forskolin (2 mM, 2 mM stock in DMSO). Unless indicated
otherwise, all control data compared with compound 1 were
from the 0.1% DMSO treatment. In ion selectivity experiments,
the symmetric solution was first used in both intra- and
extracellular sides. The cells were held at 0 mV and whole-cell
currents were recorded with a ramp from 2100 mV to +100 mV
for 500 ms. Liquid junction potential was calculated by pClampfit
9.0 software (Axon Instruments, Inc., Sunnyvale, USA) and the
corresponding reverse potential was determined. After observing a
stable whole-cell current induced by the application of 1 mM
compound 1, the bath solution was replaced by isotonic (adjusted
by sucrose) desired extracellular solution also containing 1 mM
compound 1. In these experiments, all bath solutions containing
200 mM diphenylamine-2-carboxylic acid were used to suppress
native Cl
2 channels other than those conducted to investigate the
effect of Cl
2 channel inhibitors. All patch-clamp experiments were
performed at room temperature (22–25uC).
pH-stat HPTS assay
Typically, 100 mL of the HPTS-loaded liposomes (stock
solution) was suspended in 1.9 mL of the corresponding buffer
and placed into a fluorimetric cell. HPTS emission at 510 nm was
monitored during simultaneous excitation at wavelengths of 403
and 460 nm. During each experiment, 20 mL of a 1 mM THF
solution of compound 1 (10 mM final) was added through an
injection port, followed by the injection of 20 mL of 0.5 M aqueous
NaOH. The addition of NaOH caused in increase of ca. 1 pH unit
Figure 3. The anion selectivity of synthetic Cl
2 channel 1 in HEK 293 cells. (a) The ramp stimulation protocol for whole-cell recording. (b)
The data summary for reverse potential changes when external solutions were changed from symmetric 150 mM Cl
2 to 150 mM F
2,B r
2,N O 3
2 and
I
2, respectively. All data are means 6 s.e. n=3–4. (c–f) Zoomed representative traces showing changes in reverse potential when external solutions
were changed from 150 mM Cl
2 (black traces) to 150 mM (c)F
2,( d)B r
2,( e)N O 3
2 and (f)I
2 (red traces), respectively.
doi:10.1371/journal.pone.0034694.g003
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was obtained at the end of each experiment after lysis of the
liposomes with a detergent (40 mL of 5% aqueous Triton X-100).
The final transport trace was obtained from the ratio of the
emission intensities monitored at 460 and 403 nm and was
normalized to 100% of transport.
Supporting Information
Figure S1 Current–voltage relationships obtained in the
absence ($) and presence (#) of 0.1% DMSO in HEK
293 cells.
(PDF)
Figure S2 pH-Stat ion transport assays illustrating the
ion selectivity of compound 1. All experiments employed
suspensions of EYPC liposomes containing the pH-sensitive dye
HPTS in a HEPES buffer. The intravesicular solutions were
10 mM HEPES (pH 6.8) and 100 mM NaCl and extravesicular
solutions were 10 mM HEPES (pH 6.8) and 100 mM MCl
(M=Na
+,K
+ and Cs
+)i na. Both the intra- and extravesicular
solutions contained 10 mM HEPES (pH 6.8) and 100 or 75 mM
NanX( X = C l
2,B r
2,N O 3
2,S O 4
22)i nb. At t=100 s, a THF
solution (20 mL) of the testing compound at 10 mM final
concentration was added to the extravesicular solution; 0.5 M
NaOH solution (20 mL) was then added. At t=700 s, 5% Triton
X-100 (40 mL) was added to lyse the liposomes.
(PDF)
Figure S3 The data summary of 1 mM compound 1-
increased whole-cell current densities (pA/pF) in the
absence (control) and presence of 100 mM 4,49-dithio-
cyanatostilbene -2,29- disulfonic acid (DIDS), 100 mM4 -
acetamido-49-isothiocyanostilbene-2,29-disulfonic acid
(SITS), 200 mM diphenylamine-2-carboxylic acid (DPC),
100 mM 5-nitro-2-(3-phenylpropylamino)-benzoic acid
(NPPB), and 100 mM niflumic acid (NFA), respectively,
at ±80 mV in HEK 293 cells. The cells were pretreated with
the inhibitors, respectively, for 10 min before the application of
1 mM compound 1. All data are mean 6 s.e. n=3–8, P.0.05
compared to control group.
(PDF)
Figure S4 The data summary of serum TNF-a concen-
tration of mice in the first 24 hrs after intraperitoneal
injection with DMSO, lipopolysaccharide (LPS) or
compound 1 (Comp 1). DMSO is a negative control because
it is the solvent of compound 1. LPS is a well-known endotoxin
and capably of eliciting strong immune responses in animals.
Here, LPS is a positive control. All data are mean 6 s.e. n=4–6
mice, P.0.05 compared to DMSO group. P,0.01 compared to
DMSO group.
(PDF)
Figure S5 The H & E staining images of mice lung
sections in the first 24 hrs after intraperitoneal injection
with DMSO, lipopolysaccharide (LPS) or compound 1
(Comp 1). DMSO is a negative control because it is the solvent of
compound 1. LPS is a well-known endotoxin and capably of
eliciting strong immune responses in animals. Here, LPS is a
positive control. The images show inflammatory cells (labeled by
blue arrow) infiltration in LPS treatment, but no inflammatory
cells can be found in DMSO and compound 1 treatment.
(PDF)
Figure 4. Synthetic Cl
2 channel formed by compound 1 restored cell Cl
2 permeability in CF cells. (a) Representative traces showing
whole-cell currents in CF cells. The left panel shows the stimulation protocol for whole-cell recording, and the middle panel shows DMSO control
currents. The right panel shows whole-cell currents after the application of 1 mM compound 1.( b) The current–voltage relationships obtained in the
absence (#) and presence (N)o f1mM compound 1 and after washout (m) with the control bath solution for 30 min in CuFi-8 cells. (c) Summary of
whole-cell currents at 680 mV induced by forskolin (2 mM) and compound 1 (1 mM) in CuFi-8 and NuLi-1 cells. All data are means 6 s.e. n=5–6.
doi:10.1371/journal.pone.0034694.g004
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